Overview

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
Phase:
PHASE2
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Collaborator:
Takeda Development Center Americas, Inc.
Treatments:
ZED1227